First and Second Line H. pylori Eradication Strategies in Slovenia

Phase 4, randomised, open-label trial of bismuth subcitrate, levofloxacin, amoxicillin, metronidazole and esomeprazole in Helicobacter pylori infection (4 arms), sponsored by Slovenian Society for Gastroenterology and Hepatology. Primary endpoints: Success rate of first line therapy for Helicobacter pylori infection at 2 years and Success rate of second line therapy for Helicobacter pylori infection at 3 years. Status: unknown.